Mayzent® (Siponimod) approved in Europe
The European Commission has approved oral siponimod for the treatment of adults with active secondary progressive MS
Read moreJoin the Alliance
The Alliance now includes 18 MS organisations, all working together to speed up treatments for progressive MS
Read moreSign up to our e-newsletterfor updates from our growing global initiative to end progressive MS
Clicking submit confirms that you consent to MSIF sending you the Progressive MS Alliance newsletter
Please note, you must be aged 18 or older to subscribe to our newsletters.
Click here to read our Terms & Conditions and Privacy Policy
